Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Fig. 2

Mean change from baseline in the mean scores of the EORTC QLQ-C30 global QoL scale (a), EQ-5D-5L index (b) and visual analogue scale scores (c). DOC docetaxel, EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, EQ-5D-5L EuroQoL five-dimensions, RAM ramucirumab, SD standard deviation, VAS visual analogue scale

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us